Dr. Alberto S. Pappo
Claim this profileSaint Jude Children's Research Hospital
Expert in Uterine Tumors
Expert in Brain Tumor
24 reported clinical trials
42 drugs studied
About Alberto S. Pappo
Education:
- Earned MD from Universidad Anahuac, Mexico City.
- Completed Residency at the University of Texas Health Science Center, San Antonio, Texas.
- Undertook Fellowship at Children’s Medical Center of Dallas and The University of Texas Southwestern Medical Center, Dallas, Texas.
Experience:
- Director of the Solid Tumor Division at St. Jude Children's Research Hospital, Memphis, TN.
- Research focuses on novel therapies for pediatric solid tumors, including pediatric melanoma, soft tissue sarcomas, and gastrointestinal stromal tumors.
Area of expertise
1Uterine Tumors
Global LeaderStage I
NTRK positive
Stage IV
2Brain Tumor
Global LeaderNTRK positive
NTRK1 positive
Stage IV
Affiliated Hospitals
Clinical Trials Alberto S. Pappo is currently running
Chemotherapy
for Cancer
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Recruiting2 awards Phase 326 criteria
Liposomal Irinotecan-Based Therapy
for Rhabdomyosarcoma
This is a phase II study to determine safety and efficacy of combining liposomal irinotecan with vincristine alternating with VAC in intermediate-risk patients, liposomal irinotecan with temozolomide and vincristine alternating with VAC in high-risk patients and the chemotherapy combinations when given with concomitant radiation therapy in intermediate and high risk patients. Primary Objective * Estimate event-free survival for intermediate-risk participants treated with VAC and vincristine and liposomal irinotecan (VLI) with the addition of maintenance therapy with vinorelbine and cyclophosphamide. * Estimate the event-free survival for high-risk patients treated with VAC and vincristine, liposomal irinotecan, and temozolomide with the addition of maintenance therapy with vinorelbine and cyclophosphamide. Secondary Objectives * To assess the relation between pharmacogenetic variation in CEP72 genotype and vinca alkaloid (vincristine; vinorelbine) disposition in children with rhabdomyosarcoma. * To assess the relation between the pharmacogenetic variation in drug metabolizing enzymes and drug transporters, and the pharmacokinetics of vinca alkaloids, liposomal irinotecan, and cyclophosphamide in children with rhabdomyosarcoma. * To assess the extent of inter-patient variability in the pharmacokinetics of vinca alkaloids, liposomal irinotecan, and cyclophosphamide in children with rhabdomyosarcoma, and explore possible associations between drug disposition and patient specific covariates (e.g., age, sex, race, weight). * Estimate the cumulative incidence of local recurrence and overall 3-year event-free survival in patients with low-risk disease, intermediate-risk disease or high-risk disease treated with either no adjuvant radiation or minimal volume radiation and compare these outcomes with the outcomes achieved on RMS13.
Recruiting1 award Phase 240 criteria
More about Alberto S. Pappo
Clinical Trial Related9 years of experience running clinical trials · Led 24 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Alberto S. Pappo has experience with
- Cyclophosphamide
- Carboplatin
- Larotrectinib
- Temozolomide
- Vincristine
- Etoposide
Breakdown of trials Alberto S. Pappo has run
Uterine Tumors
Brain Tumor
Rhabdomyosarcoma
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Alberto S. Pappo specialize in?
Alberto S. Pappo focuses on Uterine Tumors and Brain Tumor. In particular, much of their work with Uterine Tumors has involved Stage I patients, or patients who are NTRK positive.
Is Alberto S. Pappo currently recruiting for clinical trials?
Yes, Alberto S. Pappo is currently recruiting for 4 clinical trials in Memphis Tennessee. If you're interested in participating, you should apply.
Are there any treatments that Alberto S. Pappo has studied deeply?
Yes, Alberto S. Pappo has studied treatments such as Cyclophosphamide, Carboplatin, Larotrectinib.
What is the best way to schedule an appointment with Alberto S. Pappo?
Apply for one of the trials that Alberto S. Pappo is conducting.
What is the office address of Alberto S. Pappo?
The office of Alberto S. Pappo is located at: Saint Jude Children's Research Hospital, Memphis, Tennessee 38105 United States. This is the address for their practice at the Saint Jude Children's Research Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.